The present invention refers to amorphous and crystalline forms of the Brutons tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1- yl)piperidin-1-yl)prop-2-en-1-one (ibrutinib). In particular, the invention refers to new crystalline solvate forms of ibrutinib, a method of using these crystalline solvate forms for the preparation of essentially pure amorphous ibrutinib as well as pharmaceutical compositions that comprise essentially pure amorphous ibrutinib. Further, the invention relates to essentially pure amorphous ibrutinib for the treatment of cancer.Cette invention concerne les formes amorphes et cristallines de linhibiteur de la tyrosine kinase de Bruton (Btk) 1-((R)-3-(4-amino-3-(4-phénoxyphényl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pipéridin-1-yl)prop-2-én-1-one (ibrutinib). En particulier, linvention concerne de nouvelles formes solvatées cristallines de librutinib, un procédé dutilisation de ces formes solvatées cristallines pour la préparation dibrutinib amorphe essentiellement pur ainsi que des compositions pharmaceutiques qui comprennent ledit ibrutinib amorphe essentiellement pur. Linvention concerne en outre librutinib essentiellement pur pour le traitement du cancer.
